Advanced Oncotherapy PLC Update re admission of Subscription Shares (9667W)

TIDMAVO

RNS Number : 9667W

Advanced Oncotherapy PLC

23 August 2022

23 August 2022

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Update re admission of Subscription Shares

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, provides an update regarding the Subscription announced on 19 August 2022.

Admission, due to take place tomorrow, 24 August 2022, will now comprise 4,460,000 Subscription Shares.

Application will be made for the remaining 1,400,000 Subscription Shares to be admitted to trading on AIM ("Second Admission") and it is expected that Second Admission will occur on or around 16 September 2022. The warrants relating to the Subscription Shares being issued on Second Admission will be issued on or around 17 September 2022.

Total Voting Rights

Following Admission on 24 August 2022, the Company's enlarged issued share capital will comprise 505,831,209 Ordinary Shares, of 25 pence each ("Ordinary Shares"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights on 24 August 2022 will be 505,831,209 . Upon Second Admission, the Company's enlarged issued share capital will comprise 507,231,209 Ordinary Shares, of 25 pence each and the total number of Ordinary Shares in the Company with voting rights on Second Admission will be 507,231,209 . The aforementioned figures may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Defined terms used in this announcement shall have the same meaning as in the announcement of 19 August 2022 unless otherwise defined herein.

- ENDS -

 
 Advanced Oncotherapy plc                                        www.avoplc.com 
 Dr. Michael Sinclair, Executive                      Tel: [phone] 
  Chairman 
 Nicolas Serandour, CEO 
 
 Allenby Capital Limited (Nomad 
  and Joint Broker) 
 Nick Athanas / Liz Kirchner (Corporate               Tel: [phone] 
  Finance) 
  Amrit Nahal / Matt Butlin (Sales 
  and Corporate Broking) 
 
 SI Capital Ltd (Joint Broker) 
 Nick Emerson                                         Tel: [phone] 
 Jon Levinson                                         Tel: [phone] 
 
 FTI Consulting (Financial PR             [e-mail] 
  & IR) 
 Simon Conway / Rob Winder                            Tel: [phone] 
 

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEBKNBKQBKDFFB

(END) Dow Jones Newswires

August 23, 2022 10:09 ET (14:09 GMT)